Revolution Medicines (RVMD) CFO Jack Anders Sells Shares

What Happened
Jack Anders, Chief Financial Officer of Revolution Medicines (RVMD), reported sales of 4,053 shares on September 16, 2026. The filing shows two disposals: 61 shares at $195.00 ($11,895) and 3,992 shares at $199.30 ($795,618), totaling $807,513. The transactions are reported as sales (S) and were executed under a pre-established plan to satisfy tax withholding obligations.

Key Details

• Transaction dates/prices: 2026-09-16 — 61 shares @ $195.00; 3,992 shares @ $199.30.
• Total shares sold: 4,053; total proceeds ≈ $807,513.
• Shares owned after transaction: filing excerpt does not list a total beneficial ownership figure; it notes holdings "include 43,650 restricted stock units." (Footnote F2.)
• Notable footnote(s): F1 — transactions made pursuant to a Rule 10b5-1 instruction letter adopted May 31, 2023 to satisfy tax withholding upon RSU vesting; F2 — includes 43,650 restricted stock units.
• Filing timeliness: Form 4 filed 2026-09-18 for a 2026-09-16 transaction — appears timely (within two business days).

Context
The sale was completed under a Rule 10b5-1 plan to cover tax withholding for vested restricted stock units, which is a common, routine reason executives sell shares and does not necessarily reflect a change in the insider's view of the company. This was a sale (not a purchase), so it’s not a direct bullish signal.